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Introduction and Background
Sarcopenia is defined as ‘a syndrome of progressive and 
generalised loss of skeletal muscle mass and strength with 
a risk of adverse outcomes such as physical disability, poor 
quality of life and death’ by the European Working Group 
on Sarcopenia in Older People (EWGSOP) (1). The three 
core criteria of low muscle mass, low muscle strength and 
poor physical performance can be used both in the diagnosis 
of sarcopenia and in the assessment of its severity, with low 
muscle mass alone indicating pre-sarcopenia; associated loss of 
muscle strength or performance indicating sarcopenia; and the 
presence of all three conditions indicating severe sarcopenia. 
The International Working Group on Sarcopenia (IWGS) have 
described similar diagnostic criteria without the hierarchical 
approach defining it as poor physical performance and the 
presence of low muscle mass (2). In contrast to the definition 
used by EWGSOP, the IWGS considers muscle strength as a 
preliminary indicator of sarcopenia rather than definitive to 
diagnosis. 
Sarcopenia is primarily, though not exclusively, a disease 
of older adults (1) and can lead to multiple poor outcomes 
including frailty, disability, loss of independence and reduced 
quality of life (3). Prevalence estimates in the UK suggest that 
around 4.6% of males and 7.9% of females are affected (4), 
while in the USA, comparable population studies indicate that 
around 36.1% of older adults are affected (5). The variances 
between these two estimates are considerable and highlight the 
inconsistencies in diagnostic methods and algorithms used. A 
systematic review of 35 articles (totalling 58404 community-
dwelling participants aged 60 years and older) identified an 
overall prevalence of 10% in both men and women; this review 
also identified that the prevalence of sarcopenia was almost 
double in non-Asian individuals compared to Asians when 
Bioelectrical Impedance Analysis (BIA) was used (6). Within 
UK clinical settings, around 14-33% of those in long-term 
care were assessed to have sarcopenia (3). Global estimates 
suggest that around 50 million individuals currently have 
sarcopenia, this is estimated to rise to 200 million over the next 
40 years (1). The clinical, personal and economic implications 
of sarcopenia are therefore substantial. The direct cost burden 
to the health and social care budget in the United States in 2000 
was estimated to be approximately $18.5 billion per annum (7), 
represented by hospitalisation, nursing home admissions and 
home healthcare expenditure; this is probably an underestimate 
of the true healthcare cost.
Despite the adverse impact of sarcopenia on the individual 
and their carers, the condition remains poorly understood 
and inconsistently diagnosed and managed. Diagnostic 
identification of low muscle mass tends to be complex, 
time-consuming and costly (1, 2, 8). Once sarcopenia is 
diagnosed, the therapeutic approach is typically conservative, 
management is primarily dietary supplements and physical 
activity (9). The limited evidence available demonstrates these 
interventions can improve strength and function, improve 
quality of life and consequently reduce the economic burden 
(9–14). Whilst management is currently typically conservative 
there are ongoing clinical trials investigating the benefits 
of pharmacological approaches such as the effect of ACE 
inhibitors (14).  
The foregoing resume suggests that the current effective 
management of sarcopenia is currently non-invasive and 
relatively low-cost. This makes the case for a more proactive 
approach to intervention, since if sarcopenia is diagnosed, it 
can be cheaply and successfully managed, but if it remains 
undiagnosed, its impact can be progressively debilitating. The 
argument for routine diagnosis and management would seem, 
therefore, to be unassailable. However, a key impediment to 
the introduction of wide scale diagnosis relates to the current 
diagnostic procedures. The diagnostic algorithm suggested by 
the EWGSOP assesses muscle mass, strength and performance. 
However, many of the relevant measurement techniques for 
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measuring muscle mass have numerous flaws that make them 
unsuitable for routine use in frail older adults. Alongside the 
standard reliability and validity problems, there may also be 
poor accessibility for frail older adults, be only suitable for 
certain settings and can therefore be incompatible with the 
target population. For example, muscle mass measurement and 
calculation methods, while abundant, can also consider different 
outcomes. Depending on the device used, BIA can calculate 
total lean mass (body weight minus body fat), appendicular 
lean muscle mass (aLM - lean mass in the limbs) or both (15). 
To further complicate matters, these two measurements can 
be estimated using computed tomography (CT), magnetic 
resonance imaging (MRI), BIA and dual-energy x-ray 
absorptiometry (DXA) (1–3, 16). The benefits and limitations 
of the available measurement techniques are summarised in 
Table 1.
The synopsis presented in Table 1 suggests that, on balance, 
ultrasound may offer the most promising option for routine 
diagnosis particularly when considering a community based 
frail older adult population. There are both physical and 
cognitive limitations to the accessibility of MRI, CT and DXA 
in a frail older adult population which are not applicable to 
bedside tests such as ultrasound or BIA. However, BIA is 
dependent of hydration status and unlikely to be accurate in 
states of peripheral oedema.  
Towards a new diagnostic procedure
When the target sarcopenic population is typically frail, 
elderly and immobile, the imaging technique must be easily 
accessible, both geographically and physically, and in this 
regard ultrasound is clearly superior to the other methods 
outlined in Table 1. In particular, it offers a non-invasive, 
portable and safe imaging modality, whilst having the 
additional benefits of: maintaining image clarity, being widely 
used in medicine, familiar to clinicians, reliable and easily 
interpreted by the lay sonographer (17, 18). More specifically, 
the evidence-base for the use of ultrasound in the measurement 
of the thickness of numerous muscle groups is convincing (17, 
19–23), supporting accurate and reliable depth measurements 
across different muscles and populations. However, ultrasound 
does pose some problems, which although not insurmountable, 
would need further development before its use as a routine 
diagnostic tool could be considered. In particular, there is 
currently a lack of a clear and standardised protocol for the 
assessment of skeletal muscle, including: no widely established 
norms for the various muscle thicknesses within the non-
clinical population; there is no definitive agreement either 
about which muscle group should be measured or the probe 
site; or defined criteria for low muscle mass identification 
in sarcopenia. The heterogeneity of methods that could be 
adopted for muscle mass measurement and analysis could 
impact on future clinical and research implementation, thus it 
is imperative that a standardised and easily applied technique is 
agreed on.
Table 1
Benefits and Limitations of different modalities used in 
estimation of skeletal muscle mass
Modality Benefits Limitations
MRI • No ionising radiation
• Good for imaging soft tissues
• Able to review images after 
scanning
• Thorough image acquisition
• Expensive
• Time consuming
• Limited accessibility for frail 
community based patients and those 
with cognitive impairment
• Confined space in scanner
• Limited availability
• Cannot use if patient has metal 
work/some pacemakers
•  Requires  in terpreta t ion by 
radiologist
CT • Able to review images after 
scanning





• Confined space in scanner
• Limited availability
•  Requires  in terpreta t ion by 
radiologist
DXA • Can also identify bone mineral 
density 






• No radiation exposure
• Quick to perform
• Dependent on hydration status
• No assessment of reliability in 
dependent oedema, congestive 
cardiac failure and renal failure
• No reliability data in frail older 
adults
• Not universally portable
• Cannot use if patient has metal 
work or electronic device implants
•  Varying accuracy between 
machines
Ultrasound • Extremely safe
• No ionising radiation
• Good for imaging soft tissues





• Quick to perform
• Suitable in all patient groups
• Can be interpreted at bedside 
by a lay sonographer
• Variety of probes required to 
achieve varying depth/resolution
• Limited use in obese patients
• Quality and interpretation of 
images is user dependent
• No criteria for diagnosis of low 
muscle mass
 
Notwithstanding these concerns, there is evidence that 
ultrasound is an excellent surrogate marker of aLM (1, 23–27). 
Using regression analysis, measures of muscle depths can be 
used to predict overall skeletal muscle mass (23, 24, 28–30); 
aLM data reliably correlate with those derived from other 
measurement techniques, such as DXA-derived aLM scores 
in older adults (26). Taken together, these findings suggest 
that ultrasound is as accurate and reliable as DXA-derived 
aLM data, but is more easily obtained (26). While a composite 
measure of skeletal muscle mass is likely to be more accurate 
(26), this is not always feasible in a frail elderly population, and 
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therefore a simpler approach such as ultrasound measurement 
of muscle thickness may be superior in this population (29). 
Abe et al have suggested that ultrasound measures of forearm 
muscle thickness may be a useful measure in sarcopenia (26). 
They have shown that forearm thickness is strongly correlated 
with hand grip strength, suggesting a positive association with 
physical activity levels; this clearly requires further testing, but 
it has clinical appeal.
Furthermore, ultrasound can measure changes in muscle 
architecture and composition such as muscle echogenicity, 
pennation angle and fibre length (17). Muscle strength and 
physical performance, the other defining criteria of sarcopenia, 
are affected by not only muscle size but muscle quality 
(1). Muscle quality is defined as muscle function (strength 
or power) per unit of muscle size (mass or cross-sectional 
area) (20, 22, 31) and is affected by: the morphological 
characteristics of the muscle, aerobic capacity, intramuscular 
adipose tissue, fibrous tissue and motor units. It has been 
suggested that ultrasound can be used to determine muscle 
quality (32, 33). Ultrasound provides scope for the efficient 
assessment of muscle quality whilst providing insight into the 
pathophysiology of sarcopenia in addition to the diagnosis 
of low muscle mass. Previous research has demonstrated 
that echogenicity increases with age, whilst the pennation 
angle of muscles decreases (17, 34, 35). The relationship 
between muscle size, quality and function is as yet incompletely 
characterised and a move to assessing both size and quality 
simultaneously would improve our understanding.
Ultrasound echogenicity has been particularly highlighted 
as a technique to measure muscle quality. Ultrasound 
echogenicity refers to the capacity of any tissue to reflect and 
absorb ultrasound waves, and can be calculated using grayscale 
analysis derived from ultrasound imaging (36). In essence, 
the whiter the image the higher the proportion of slow-twitch 
muscle fibre and intra-muscular adipose tissue; high ultrasound 
echogenicity values have been correlated with lower muscle 
quality and grip strength (21, 22, 37). An example of the 
differences in ultrasound echogenicity in sarcopenic older 
adults compared to healthy younger adults is depicted in Figure 
1. This aspect of the ultrasound image can therefore be used as 
an index of muscle quality. The correlation of intramuscular 
adipose tissue, as demonstrated by grayscale analysis, with 
various muscle performance measures, such as grip strength 
and walk speed, needs to be more thoroughly assessed; if 
their association can be reliably established, then the value 
of ultrasound imaging in sarcopenia diagnosis is further 
strengthened. Whilst a direct relationship between adipose 
infiltration and muscle weakness is not yet fully understood, 
there are several potential mechanisms explaining the 
phenomenon (38–41). As there are many factors contributing to 
muscle strength, echogenicity analysis of muscles may offer an 
insight into the pathophysiology of sarcopenia rather than act as 
a direct measurement technique. 
Figure 1
Ultrasound echogenicity of healthy younger and sarcopenic 
older adult 
Recommendations and conclusions
The foregoing overview suggests that ultrasound may be 
a valuable potential diagnostic tool enabling the easy routine 
diagnosis of low muscle mass. While there are several 
obstacles (summarised above) that need to be negotiated before 
ultrasound can be confidently adopted into clinical practice, 
it is undoubtedly the case that the current gold standards of 
muscle mass measurement may be neither accessible nor 
suitable for assessing the frail older adult. What is clearly 
required is a pragmatic diagnostic tool that is: simple, easily 
and unambiguously interpreted, non-invasive, poses no risk, 
and can be used within both community and hospital settings. 
Ultrasound meets these requirements and offers portability, 
cost-effectiveness and speed in addition. However, while its use 
appears promising, the evidence-base needs to be established 
and a standardised protocol developed. In-depth comparisons 
with other gold-standard data are essential to establish its 
validity and reliability, while a normative data-set for the 
creation of low muscle mass criteria also needs to be collated. 
Forearm muscle depth could be an especially valuable tool as a 
diagnostic technique that does not require removal of clothes or 
transferring of individuals. 
Ultrasound might be an important addition to the diagnostic 
tool-box, allowing quick and early diagnosis of sarcopenia 
and facilitating appropriate dietary and exercise interventions. 
Besides the obvious benefits to the individual and the carer, 
the cost implications for the health service are minimal, while 
the savings are considerable. The potential value of ultrasound 
muscle screening for older adults and their care providers is 
worthy of further consideration and investigation.
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